Synonyms: REGN475 | SAR164877
Compound class:
Antibody
Comment: Fasinumab is an investigational, fully human IgG4κ monoclonal antibody targeting nerve growth factor (NGF).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches to peptide sequences submitted with patent US7988967 [4], with the preferred antibody being called REGN475 therein. REGN475 exhibits high specificity for human NGF, does not cross-react with closely related neurotrophin-3 (NT-3) and inhibits binding of NGF to its receptors TrkA (NTRK1) and p75 (NGFR) [4]. |
Bioactivity Comments |
Fasinumab (REGN475) blocks NGF binding to its receptors TrkA and p75 with IC50 values of 20 and 22 pM respectively, and inhibits NGF-mediated TrkA/p75 signalling in PC12 cells with IC50 of 9.6pM [4]. A proof-of-concept study reported that fasinumab provided no clinical benefit in patients with acute sciatic pain [5]. |
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|